Results 151 to 160 of about 75,705 (253)

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Multivalent antibody‐based conjugates as new tools for tailored modulation of G protein–coupled receptors

British Journal of Pharmacology, EarlyView.
The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley   +1 more source

Diagnosis of Growth Hormone Deficiency in Children: Comparative Performance of Arginine Versus Glucagon as the First Stimulation Test

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Growth hormone deficiency (GHD) diagnosis typically requires the performance of two sequential stimulation tests. Glucagon stimulation test (GST) and arginine stimulation test (AST) are widely used. This study aimed to determine the most suitable order of tests.
David Shaki, Daria Shvarts, Eli Hershkovitz, Lior Carmon, Hazan Guy, Bachar Yoav, Alon Haim   +6 more
wiley   +1 more source

A Reporter Gene Assay for Measuring the Biological Activity of PEGylated Recombinant Human Growth Hormone. [PDF]

Molecules
Hu S, Zhang X, Li Y, Li J, Wang Y, Liang C.   +5 more
europepmc   +1 more source

Growth Hormone Treatment Response and Machine Learning‐Based Prediction in Idiopathic GHD and ISS: Analysis of the Korean LG Growth Study

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Individual responses to recombinant human growth hormone (rhGH) therapy vary widely among children with idiopathic growth hormone deficiency (iGHD) and idiopathic short stature (ISS), making accurate prediction of treatment outcomes clinically important.
Jisun Park, Eun Young Joo, Su Jin Kim, Myung Ji Yoo, Ji Eun Lee   +4 more
wiley   +1 more source

Comparison of the effectiveness of recombinant human growth hormone therapy in preterm and full-term children with short stature born small for gestational age. [PDF]

Ann Pediatr Endocrinol Metab
Kim D, Yoon JH, Hwang S, Kim JH, Yoo HW, Choi JH.   +5 more
europepmc   +1 more source

Steroidogenic compensation and lipid deficiency with enhanced NAD+ salvage in small‐for‐gestational‐age placenta

The FEBS Journal, EarlyView.
Fetal growth restriction is associated with placental metabolic adaptations. In small‐for‐gestational‐age placenta (SGA), cholesterol receptors and steroidogenic enzymes are upregulated, enhancing steroidogenesis. NAD salvage pathway is also increased to support NADP+/NADPH requirements.
Serena Xodo, Lorenza Driul, Vanessa Tolotto, Eros Di Giorgio, Luigi E. Xodo   +4 more
wiley   +1 more source

Investigating transthyretin variants H88R and I107V in amyloid priming: From destabilization to complete dissociation

The FEBS Journal, EarlyView.
Investigated mutations in transthyretin (TTR) disrupt the F87‐centered hydrophobic core that stabilizes its tetrameric structure. The mild I107V mutation weakens inter‐chain packing, while H88R fully abolishes tetramer formation, yielding a monomeric, aggregation‐prone form. Structural, biophysical, and computational analyses reveal that both mutations
István L. Bódy, Zsolt Fazekas, Nóra Wágner, Anna J. Kiss‐Szemán, Veronika Harmat, Zoltán Pozsonyi, Dóra K. Menyhárd, András Perczel   +7 more
wiley   +1 more source

Recombinant human growth hormone therapy in a Chinese patient with trichorhinophalangeal syndrome I and growth hormone deficiency

Asian Journal of Surgery
Yujie Li, Ke Huang, Wei Wu, Guanping Dong   +3 more
doaj   +1 more source

Membrane‐type I metalloproteinase (MT1‐MMP): A key modifier of extracellular matrix microenvironment

The FEBS Journal, EarlyView.
MT1‐MMP: A cellular microenvironment modifier. MT1‐MMP is a major cellular microenvironment modifier, maintaining collagen homeostasis by degrading excess collagen (A), creating a migration path in motile cells such as cancer cells (B), modulating local microenvironmental signaling by cleaving transmembrane receptors (C), and destroying tissue ...
Yoshifumi Itoh, Masaki Inada
wiley   +1 more source